7 Best Peptides for Female Fertility

What to Know Before Choosing a Peptide for Female Fertility

The landscape of peptides discussed for female fertility is unusually wide. Some of these compounds have completed randomized controlled trials and generated genuine clinical evidence. Others are used routinely in community protocols and functional medicine settings without a single published human fertility trial behind them. Both kinds belong in this guide, because both kinds show up in the conversations women are actually having about fertility support.

A peptide earns a slot here because people use it or are actively discussing using it for this goal. FDA-approved, telemedicine-prescribed, and research-only compounds are all eligible. Evidence strength shapes how honestly each entry describes what a compound can and cannot claim, not whether it appears at all. A compound with thin or absent human trial data is included with that stated plainly. A compound with Phase 2 trial results is described as having Phase 2 trial results. The standard is honesty, not gatekeeping.

The entries below are numbered for structure, not as a verdict. The ordering reflects how prominently each compound appears in research and documented real-world use for female fertility, not a recommendation that one is better than another for you. The right compound depends on your specific situation, your health history, and what you build from here. These entries give you the map. The app helps you turn that map into a plan.

1. Kisspeptin-10: The Compound at the Center of Fertility Research

Kisspeptin-10 is the shortest active fragment of the kisspeptin peptide family, sharing the same C-terminal receptor-binding sequence as the longer isoforms studied in clinical trials. It works by binding to a receptor on neurons in the hypothalamus called Kiss1R, which functions as the on-switch for the hormonal cascade that drives ovulation. When kisspeptin binds that receptor, it triggers the release of GnRH, the signaling molecule that tells the pituitary gland to release LH and FSH. Those two hormones then drive follicle development, egg maturation, and the LH surge that precedes ovulation. That entire chain runs from a single binding event in the hypothalamus all the way to what happens in the ovary, which is why the kisspeptin family has attracted serious clinical attention.

The clinical evidence worth understanding here comes primarily from Kisspeptin-54, the longer isoform, rather than from Kisspeptin-10 specifically. Researchers at Hammersmith Hospital completed Phase 2 trials in which a single injection of KP54 was used as an ovulation trigger in IVF, producing live births with zero cases of ovarian hyperstimulation syndrome, a dangerous complication that standard triggers like hCG carry real risk of causing. A subsequent Phase 2 trial in 60 high-risk patients confirmed the safety signal across a range of doses. A related compound, MVT-602, completed two randomized trials in 2024 in healthy premenopausal women and produced an LH surge pattern that closely mirrors the body's natural midcycle response, something no current standard trigger achieves. Kisspeptin-10 itself does not have independent fertility trial data separate from the larger family, but it is the form most widely available outside clinical settings and most often discussed by women with PCOS or hypothalamic amenorrhea who are trying to support ovulation through the same mechanism the trials established.

Community use patterns for Kisspeptin-10 come with real caveats. The compound requires pulsatile administration timed carefully to the menstrual cycle. People who do not respond often trace that back to single daily injections rather than the pulsatile dosing the biology requires. Because egg maturation runs on a roughly 90-day cycle, any effect on egg quality takes two to four months to become apparent. Community tracking suggests fewer than 12 percent of users have reported quantitative evidence, such as bloodwork, to support the benefits they attribute to the compound. The gap between how widely Kisspeptin-10 is discussed and how well-measured its real-world results are is worth holding in mind. The clinical science behind the mechanism is genuine. The translation from clinical-setting kisspeptin to self-administered Kisspeptin-10 is a different, less-established step.

2. Gonadorelin: The Established Hormonal Reset

Gonadorelin is a synthetic analog of GnRH, the signaling molecule the hypothalamus naturally uses to tell the pituitary to release LH and FSH. Unlike kisspeptin, which works upstream of GnRH neurons to trigger their firing, gonadorelin mimics the GnRH signal directly at the pituitary. When delivered in a pulsatile pattern that mirrors the body's natural GnRH rhythm, it restores the hormonal cascade that drives follicle development and ovulation in women whose own hypothalamus is not generating adequate signals.

Decades of established clinical use back gonadorelin for one specific indication: hypothalamic amenorrhea, the condition in which the hypothalamus stops sending adequate GnRH pulses and shuts down the menstrual cycle. Women with this condition, often tied to low body weight, high training loads, or chronic stress, have seen ovulatory cycles restored through pulsatile gonadorelin administration. That clinical record is the reason this compound sits near the top of most practitioner discussions about peptide options for fertility.

The practical situation in 2026 is more complicated. Both US commercial products are discontinued. Access in the United States now runs through compounding pharmacies, and that channel has been narrowing following FDA safety communications. Women using gonadorelin today are typically doing so via a prescribing physician and a compounding pharmacy, not through research-chemical channels. That distinction matters for how realistic access actually is, and it is worth a direct conversation with a clinician before expecting this to be a simple option.

3. cFEE (Fertiline): The Strongest Trial Evidence Outside Kisspeptin

cFEE, developed under the name Fertiline at Institut Cochin in France after roughly 30 years of research, occupies a genuinely unusual position in this field. It holds the strongest prospective randomized clinical trial evidence of any compound on this list specifically for improving fertility outcomes in IVF, and it is almost entirely absent from English-language community discussions because it has not yet reached widespread clinical use or the research-chemical market.

The Phase 2 trial, authorized by the French Agence de la BioMedecine, found that cFEE improved immature oocyte maturation rates by more than 50 percent, reduced miscarriage rates, and increased birth rates by 7 percent in the treated group compared to controls, rising to 13 percent in the best-prognosis embryo cohort on first transfer. A Phase 3 trial involving 360 couples across 8 centers is currently underway, with results expected around 2025, to support a marketing authorization request. The mechanism is distinct from every other compound here: cFEE targets oocyte and embryo ploidy, meaning the chromosomal normality of eggs and embryos, and appears to improve the maturation rate of immature oocytes retrieved during IVF cycles.

This compound is not yet accessible outside clinical trials. It is not available through compounding pharmacies, research-chemical suppliers, or functional medicine clinics. It appears in this guide because it is being actively studied, the existing evidence is real and independently reviewed, and women researching fertility peptides deserve to know it exists and where it stands. The gap between its evidence quality and its current availability is wide, but Phase 3 results and a potential path to clinical approval are on the near horizon.

4. Sermorelin: For Ovarian Reserve and Egg Quality Support

Sermorelin is a growth hormone-releasing hormone analog, FDA-approved for growth hormone deficiency and used off-label in adults for a range of purposes including, in functional medicine and biohacking contexts, fertility support. Its fertility-relevant action runs through IGF-1: sermorelin stimulates GH release from the pituitary, which raises circulating IGF-1, a growth factor that supports ovarian function and follicle development. IGF-1 receptors are expressed throughout ovarian tissue, and IGF-1 signaling plays an active role in folliculogenesis, the process by which follicles mature and produce eggs.

The off-label use case for sermorelin in fertility focuses on two areas: supporting ovarian reserve in women with low baseline IGF-1, and improving egg quality in women preparing for IVF, particularly those over 35. Some protocols call for a lead time of three to six months before an IVF cycle, based on the logic that the 90-day egg maturation window means interventions started too close to retrieval arrive too late to influence that cycle's eggs. The biological rationale for these applications is solid. Direct human trial data showing that sermorelin improves pregnancy rates or live birth rates is not available in peer-reviewed literature. A claimed multicentre trial combining sermorelin with another peptide and citing specific pregnancy rate figures has not been verifiable in major peer-reviewed databases and should not be taken as established evidence.

Sermorelin is legally prescribed by physicians and used off-label under physician supervision in functional medicine settings. Women accessing it for fertility support are typically doing so through a prescribing clinician, which gives this compound a different practical standing than the research-only options in this field.

5. Epithalon: For Oocyte Aging and Cellular Longevity

Epithalon is a tetrapeptide derived from the pineal gland and part of the broader family of Khavinson peptide bioregulators. Its proposed primary mechanism involves the activation of telomerase, the enzyme that maintains the protective caps on chromosomes, along with reduction of oxidative stress in aging cells. Oocytes in women over 35 accumulate oxidative damage and chromosomal instability over time. The theoretical case for Epithalon in fertility is that by supporting DNA repair and reducing oxidative stress at the cellular level, it may help preserve or restore the quality of aging egg cells.

No fertility-specific randomized controlled trials have been published for Epithalon in humans. The evidence base is preclinical and mechanistic. Broader Epithalon research on telomerase activation and oxidative stress reduction in aging tissue provides the biological rationale that leads people to reach for it in fertility stacks, but none of that research was conducted in reproductive tissue with fertility outcomes as the endpoint. The use here is entirely extrapolated from anti-aging biology.

Community use places Epithalon most often in protocols designed for women over 35 concerned about egg quality, where it is sometimes combined with mitochondrial-support compounds in what users describe as a cellular-aging approach to oocyte quality. The underlying logic is not unreasonable given the biology. The evidence for any specific fertility outcome remains preclinical and theoretical, and that is how it should be described to anyone considering it.

6. Thymosin Alpha-1: For the Immune Side of Implantation

Thymosin Alpha-1 is a 28-amino acid peptide that modulates immune function, particularly the activity of regulatory T-cells. These are the immune cells responsible for suppressing inappropriate immune responses, and they are central to successful embryo implantation. The embryo is genetically half-foreign to the mother's immune system. For implantation to succeed, the uterine immune environment must tolerate rather than attack it. Regulatory T-cells are the key mechanism behind that tolerance. The proposed case for Thymosin Alpha-1 in fertility is that by supporting regulatory T-cell activity, it may improve the immune environment at the maternal-fetal interface, reducing immune-mediated implantation failure.

This application is emerging rather than established. No randomized controlled trials have tested this mechanism in a fertility-specific human population. The evidence is mechanistic and early-stage, drawn from immunology research on T-cell regulation rather than from studies measuring conception or implantation success rates. The clinical interest in this direction focuses specifically on women with recurrent implantation failure or autoimmune conditions that may compromise the uterine environment.

Community interest in Thymosin Alpha-1 for fertility is more limited than for other compounds in this guide. It appears primarily in specialist functional medicine protocols rather than general biohacking fertility stacks, and it is most relevant when the fertility challenge is implantation rather than ovulation or egg quality. For women in that situation, it represents a biologically coherent direction worth discussing with a knowledgeable physician, with the clear understanding that human trial data for this specific application does not yet exist.

7. Zhenoluten: The Ovarian Peptide Bioregulator

Zhenoluten is an ovary-targeted peptide bioregulator, part of the family of short peptides developed through the research of Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. Peptide bioregulators in this tradition are typically short chains of two to four amino acids derived from specific organ tissues. The proposed mechanism is that these short peptides penetrate cells, bind to DNA regulatory regions, and switch on gene expression patterns in the targeted tissue that have declined with age or dysfunction. For Zhenoluten specifically, the target is ovarian tissue, and the proposed effect is the restoration of follicular function and oocyte quality by reactivating cellular programs that have become dormant.

No clinical trial data for Zhenoluten and female fertility outcomes appears in major Western clinical trial registries. The published research that exists comes primarily from Russian-language literature and from Khavinson's own institute, which is a narrower and less independently verified evidence base than what exists for most compounds in this guide. Western peer review of the peptide bioregulator framework as a whole remains limited. That is an honest assessment of where things stand, and it is the reason this compound appears at the end of this list despite the real community interest it generates.

The practical interest is genuine. Zhenoluten appears consistently in community discussions about female fertility, it is used by women with diminished ovarian reserve and age-related fertility concerns, and it is often combined with other Khavinson peptides or with Epithalon in approaches practitioners describe as targeted ovarian support. It is available in capsule and injectable forms through specialty bioregulator suppliers, primarily serving Eastern European markets, and is sometimes bundled into female fertility stacks alongside other compounds in this guide. The evidence here is experiential and framework-based rather than derived from independently replicated human trials, and anyone considering it should enter that territory with clear eyes about what has and has not been formally tested.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for female fertility?

No peptide is currently FDA-approved specifically as a female fertility treatment for general infertility. PT-141 holds FDA approval for hypoactive sexual desire disorder in premenopausal women, which is a separate indication. Some peptides used in IVF protocols carry FDA approval for specific reproductive medicine uses but are not marketed as general fertility peptides. Kisspeptin analogs are in Phase 2 and Phase 3 trials and may reach clinical approval within a few years.

How is the evidence for fertility peptides different from the evidence for other peptide applications?

Fertility outcomes are among the hardest to measure in clinical trials because they require following participants through conception, implantation, and live birth, which takes far longer and costs far more than trials measuring a biomarker or a symptom score. That is part of why most compounds discussed for fertility have strong mechanistic rationale but thin human outcome data. The exceptions, kisspeptin analogs and cFEE, are notable precisely because they did the difficult work of tracking actual fertility outcomes in randomized trials.

What does it mean that egg maturation takes 90 days?

The egg that ovulates in any given cycle began its maturation roughly three months earlier. Any intervention aimed at improving egg quality, whether through hormonal signaling, mitochondrial support, or cellular repair, needs to be in place well before the cycle in which you hope to see its effect. This is why functional medicine protocols typically call for three to six months of preparation before an IVF retrieval, and why users in community settings report that changes attributed to fertility peptides take at least two to four months to become apparent.

Is it safe to use these peptides while trying to conceive?

This is a question that requires a physician. The safety profiles for most of these compounds during a conception attempt are unknown, and unknown is not the same as safe. Standard guidance in functional medicine settings calls for stopping non-essential peptide protocols at least 30 days before actively trying to conceive. GH-axis peptides carry additional caution given theoretical concerns about unintended cell proliferation. None of these should be self-administered during a conception attempt without guidance from a clinician familiar with your full health history.

Why is Kisspeptin-10 different from the kisspeptin used in clinical trials?

The clinical trials that produced live births and the zero-OHSS safety data used Kisspeptin-54, the full-length isoform, administered in a clinical setting as a precisely timed ovulation trigger. Kisspeptin-10 is the shortest active fragment of the same peptide family and shares the receptor-binding sequence, which is why it activates the same pathway. No independent clinical trial has tested Kisspeptin-10 specifically for fertility outcomes, the dosing and timing requirements in a self-administered setting are not standardized, and the gap between the clinical-trial compound and the research-chemical market version is meaningful.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for female fertility in one place.